James Deangelo, DO
Allergy · Pittsburgh, PANPI 1922056530
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Biocryst US Sales Co., LLC at 55.1% of the total. Reporting peaked in 2022 at $31,011 and has fallen 64.8% since, to $10,923 in 2025. Among allergy clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 508 payments — averaging $156.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst US Sales Co., LLC$44K
- Shire North American Group Inc$12K
- Biocryst Pharmaceuticals, Inc.$9K
- Pharming Healthcare, Inc.$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AstraZeneca$1K
- plus $7K from 30 others
Across 261 payments — averaging $5516.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$528K
- Seqirus USA Inc$345K
- Novartis$259K
- Teva Pharmaceuticals USA, Inc.$126K
- Regeneron$88K
- Octapharma USA, Inc.$49K
- plus $44K from 4 others
What the payments were for
- Consulting fees$29,13937%
- Speaking & faculty fees$33,39342%
- Travel & lodging$6,1758%
- Food & beverage$10,25013%
- Education$3860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst US Sales Co., LLC | 65 | $43,743 |
| Shire North American Group Inc | 20 | $11,551 |
| Biocryst Pharmaceuticals, Inc. | 16 | $9,269 |
| Pharming Healthcare, Inc. | 6 | $4,073 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $1,856 |
| AstraZeneca | 64 | $1,398 |
| Alk-abello, Inc | 10 | $1,395 |
| GSK | 78 | $1,198 |
| Regeneron Healthcare Solutions, Inc. | 40 | $1,084 |
| Sanofi | 34 | $708 |
| Grifols USA, LLC | 32 | $681 |
| CSL Behring | 26 | $557 |
| Genentech USA, Inc. | 19 | $393 |
| Pfizer | 14 | $271 |
| Novartis | 8 | $201 |
| Sanofi-aventis U.S. LLC | 2 | $157 |
| Amgen | 7 | $128 |
| LEO Pharma Inc. | 4 | $83 |
| Verona Pharma, Inc. | 3 | $60 |
| Kaleo, Inc. | 4 | $58 |
| Optinose US, Inc. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 1 | $45 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $45 |
| GC Biopharma USA, Inc. | 2 | $42 |
| Cycle Pharmaceuticals Inc | 2 | $41 |
| Vifor Pharma, Inc. | 2 | $38 |
| Bio Products Laboratory USA, Inc. | 3 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Blueprint Medicines Corporation | 1 | $28 |
| Merck | 1 | $25 |
| Lilly USA, LLC | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Octapharma USA, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Jubilant Hollisterstier LLC | 1 | $15 |
| Covis Pharma GmbH | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,343 in reported general payments places this provider in the 95th percentile of 25 allergy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 21 | $1,079,704 |
| Fasenra PenBenralizumab | 21 | $120,695 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $58,022 |
| Dupixent PenDupilumab | 14 | $51,525 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $25,660 |
| Arnuity ElliptaFluticasone Furoate | 28 | $12,307 |
| Fluticasone Propionate HfaFluticasone Propionate | 33 | $11,322 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $9,144 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $8,138 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $7,177 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $5,118 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $4,344 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $4,138 |
| Fluticasone Propionate | 108 | $3,725 |
| AsmanexMometasone Furoate | 13 | $3,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $1,856 | $1,079,70421 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,198 | $95,989109 claims |
| AstraZenecaSymbicort | $1,398 | $7,17713 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $45 | $4,34412 claims |
| MerckAsmanex | $25 | $3,37013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 allergy providers in Pennsylvania.
Other allergy in Pittsburgh
- Michael PalumboPittsburgh$561K
- David MillerPittsburgh$7K
- Allyson LarkinPittsburgh$1K
- Richard GreenPittsburgh$139
- Andrew VayonisPittsburgh$15
- Shannon KearneyBethlehem$48K
- Rehan MujahidWind Gap$16K
- Schweta ArakaliAllentown$12K
- Michelle WeissYork$7K
- Andrew MurphyWest Chester$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.